If you are on Medicare and wondering whether your Part D plan will cover a GLP-1 medication in 2026, you are not alone. The landscape has shifted substantially thanks to the Inflation Reduction Act (IRA), new FDA approvals, and evolving CMS guidance. This guide covers everything you need to know — from which drugs are on formulary to what you will actually pay out of pocket.
What Changed for Medicare GLP-1 Coverage
Before 2025, Medicare Part D coverage for GLP-1 medications was limited almost entirely to type 2 diabetes indications. Drugs like Ozempic and Rybelsus were covered because they had diabetes approvals, but weight-management-only drugs like Wegovy were explicitly excluded under Part D's statutory anti-obesity drug exclusion.
Two major changes broke that pattern:
- The Inflation Reduction Act (2022, phased in through 2025) — introduced a $2,000 annual out-of-pocket cap for Part D, eliminated the coverage gap ("donut hole") cost-sharing spike for most beneficiaries, and gave CMS new negotiation authority over high-cost drugs.
- The TREAT Act provisions (signed into law late 2024) — ended the decades-old Part D exclusion of anti-obesity medications, meaning Medicare can now cover FDA-approved weight loss drugs starting in 2026 plan year formularies.
Together, these changes mean that for the first time, Medicare beneficiaries can access GLP-1 medications for both diabetes and obesity through Part D, with meaningful out-of-pocket protections.
Which GLP-1 Medications Are Covered
Coverage varies by plan, but here is the general landscape for 2026:
Covered for Type 2 Diabetes (Most Plans)
- Ozempic (semaglutide injection) — widely covered on most Part D formularies, typically Tier 3 or Tier 4. Prior authorization is common but approval rates are high for diabetes patients with documented A1C levels.
- Rybelsus (oral semaglutide) — available on many formularies as an oral alternative. Some plans prefer it over Ozempic because it is oral and slightly less expensive.
- Mounjaro (tirzepatide) — covered for type 2 diabetes on most plans. Tier placement varies; some plans put it on a specialty tier.
- Trulicity (dulaglutide) — still covered on many formularies, often at a lower tier than newer agents.
- Foundayo (orforglipron) — the newest oral GLP-1, increasingly appearing on 2026 formularies. Coverage is plan-dependent.
Covered for Weight Management / Obesity
- Wegovy (semaglutide 2.4mg injection) — the first GLP-1 widely covered for obesity under the new TREAT Act provisions. Prior authorization requirements are strict: most plans require BMI ≥30 (or ≥27 with a weight-related comorbidity), documented failure of lifestyle modification, and sometimes step therapy through lower-cost agents first.
- Zepbound (tirzepatide for obesity) — coverage is expanding but less universal than Wegovy in the first year. Some Part D plans are still evaluating formulary placement.
Coverage Comparison by Indication
| Medication | Diabetes Coverage | Obesity Coverage | Typical Tier | Prior Auth Required |
|---|---|---|---|---|
| Ozempic | Yes (most plans) | No (diabetes label only) | Tier 3–4 | Usually yes |
| Rybelsus | Yes (many plans) | No | Tier 3 | Sometimes |
| Mounjaro | Yes (most plans) | No (Zepbound is the obesity label) | Tier 4–5 | Yes |
| Wegovy | N/A | Yes (expanding) | Tier 4–5 | Yes (strict) |
| Zepbound | N/A | Yes (limited plans) | Tier 5 | Yes (strict) |
| Foundayo | Yes (growing) | Plan-dependent | Tier 3–4 | Yes |
| Trulicity | Yes | No | Tier 3 | Sometimes |
Step Therapy and Prior Authorization
Almost every Part D plan requires prior authorization for GLP-1 medications. This means your doctor must submit documentation proving medical necessity before the pharmacy can fill the prescription. Here is what plans typically require:
For Diabetes Indications
- Documented A1C level (usually ≥7.0% or inadequate control on current therapy)
- Trial of metformin first (unless contraindicated)
- Some plans require trial of a sulfonylurea or SGLT2 inhibitor before approving a GLP-1
- Documentation from your prescribing physician
For Obesity / Weight Management
- BMI ≥30 kg/m², or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
- Documentation of a structured diet and exercise program (typically 3–6 months)
- Some plans require trial of a lower-cost weight loss medication first (phentermine, orlistat, or contrave)
- Letter of medical necessity from your physician explaining why GLP-1 therapy is appropriate
Prior authorization approvals typically take 3–10 business days. If your initial request is denied, you have the right to appeal — and appeal success rates for GLP-1s are surprisingly high when proper documentation is submitted.
The $2,000 Out-of-Pocket Cap Explained
The single most impactful change from the Inflation Reduction Act for GLP-1 users is the $2,000 annual out-of-pocket maximum. Before this cap, Medicare beneficiaries in the coverage gap (donut hole) were responsible for 25% of brand-name drug costs, which for a GLP-1 costing $1,000+/month could mean $250+ per month in copays during the gap phase alone.
Here is how the new structure works:
- Deductible phase: You pay 100% of drug costs until you meet your plan's deductible (up to $590 in 2026).
- Initial coverage phase: You pay your plan's copay or coinsurance (typically $47–$100/month for a Tier 3–4 GLP-1).
- Coverage gap (donut hole): Previously a cost cliff. Now, once your total out-of-pocket spending hits $2,000, you enter the catastrophic phase immediately.
- Catastrophic phase: $0 copays for the rest of the year.
For a beneficiary taking a GLP-1 that costs $1,000/month retail, hitting the $2,000 cap typically happens around month 3–5 depending on your plan's cost-sharing structure. After that, your GLP-1 is essentially free for the remainder of the calendar year.
Example Monthly Cost Breakdown
| Month | Phase | Your Cost (Approx.) | Cumulative OOP |
|---|---|---|---|
| January | Deductible | $590 | $590 |
| February | Initial Coverage | $75 | $665 |
| March | Initial Coverage | $75 | $740 |
| April | Initial Coverage | $75 | $815 |
| May–August | Initial Coverage | $75/mo | $1,115–$1,415 |
| September | Hits $2,000 cap | ~$75 | $2,000 |
| Oct–Dec | Catastrophic | $0 | $2,000 |
Actual costs vary by plan. This example assumes a $75/month copay in the initial coverage phase. Some plans charge more or less.
How to Appeal a Medicare Part D GLP-1 Denial
If your Part D plan denies coverage for a GLP-1 medication, you have five levels of appeal. Most cases are resolved at Level 1 or Level 2:
- Coverage Determination Redetermination (Level 1): Your plan must respond within 7 days (72 hours for expedited). Have your doctor submit a detailed letter of medical necessity, relevant lab work, and documentation of prior therapy trials.
- Independent Review Entity (Level 2): If Level 1 fails, an independent organization (not your plan) reviews the case. Success rates increase significantly at this level because the reviewer is not financially motivated to deny coverage.
- Office of Medicare Hearings and Appeals (Level 3): Administrative law judge hearing. Rarely necessary for GLP-1 cases.
- Medicare Appeals Council (Level 4): Review of ALJ decision.
- Federal District Court (Level 5): Final judicial review.
Key tips for a successful appeal:
- Include your physician's letter explaining why the specific GLP-1 is medically necessary (not just preferred)
- Document all prior medications tried and why they were inadequate
- Include relevant lab results (A1C, fasting glucose, lipid panels, BMI history)
- Reference the specific FDA approval and indication that matches your diagnosis
- Request an expedited review if you are currently without medication
Choosing a Part D Plan With GLP-1 Coverage
During Medicare Open Enrollment (October 15 – December 7), you can switch Part D plans. Here is how to find one with strong GLP-1 coverage:
- Use the Medicare Plan Finder at Medicare.gov. Enter your specific medications to compare plans side by side, including estimated annual costs.
- Check tier placement: A GLP-1 on Tier 3 will cost substantially less than the same drug on Tier 5 (specialty tier).
- Look at prior authorization requirements: Some plans have simpler PA processes than others.
- Compare total annual cost, not just monthly premiums: A plan with a $0 premium but $150/month GLP-1 copay costs more annually than a plan with a $30 premium and $50 GLP-1 copay.
- Consider Medicare Advantage plans: Some MA-PD plans negotiate better GLP-1 pricing through integrated pharmacy benefits.
Tips for Reducing GLP-1 Costs on Medicare
- Apply for Extra Help (Low Income Subsidy): If your income is below 150% of the federal poverty level, you may qualify for Extra Help, which significantly reduces copays and eliminates the coverage gap.
- Use manufacturer savings programs: Some GLP-1 manufacturers offer Medicare-specific assistance programs. Eli Lilly and Novo Nordisk both have patient assistance programs for qualified beneficiaries.
- Ask about the Medicare Savings Program: Your state may help pay Part D premiums and cost-sharing if you qualify.
- Time your enrollment: If starting a GLP-1 mid-year, factor in the $2,000 cap — you may hit it faster than expected, giving you free coverage for the remaining months.
- Talk to a SHIP counselor: State Health Insurance Assistance Programs provide free, unbiased counseling on Medicare plan selection. Find yours at shiphelp.org.
Bottom Line
Medicare Part D GLP-1 coverage in 2026 is better than it has ever been. The $2,000 out-of-pocket cap means that even expensive medications become affordable by mid-year. The TREAT Act has opened the door for obesity-indication coverage. And the number of plans including GLP-1s on formulary continues to grow. The key is choosing the right plan during open enrollment, getting your prior authorization documentation in order, and knowing how to appeal if you hit a roadblock.
For a broader look at which GLP-1 medications are available and how they compare, see our overview of Medicare GLP-1 coverage and our guide to GLP-1s without insurance.